NovelStem International Corp. develops novel diagnostic technology that can predict patients resistance to chemotherapy allowing for cancer treatments and the potential to reduce resistance to chemotherapy. The company is headquartered in Boca Raton, Florida. The firm's primary assets are NewStem Ltd (NewStem) and NetCo Partners (NetCo). NewStem focuses on the development and commercialization of diagnostic technology that can predict patients’ anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. NewStem is principally focused on utilizing proprietary human Pluripotent Stem Cells (hPSCs) and Haploid human Pluripotent Stem Cells (HhPSCs) in the development of diagnostic and therapeutic products in oncology. Its NewStem Software Diagnostic Device (NSDD) is a bioinformatics-based software medical device platform that provides oncologists with information regarding the presence of mutations in tumors, which may confer patient resistance to certain anti-cancer drugs. NetCo is a media business interest which owns Net Force, a book publishing franchise.
Follow-Up Questions
Novelstem International Corp 的 CEO 是誰？
Mr. Jan Loeb 是 Novelstem International Corp 的 Executive Chairman of the Board，自 2018 加入公司。
NSTM 股票的價格表現如何？
NSTM 的當前價格為 $0.018，在上個交易日 decreased 了 0%。
Novelstem International Corp 的主要業務主題或行業是什麼？
Novelstem International Corp 屬於 Biotechnology 行業，該板塊是 Health Care
